The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double‐Blind Randomized Controlled Trial
ABSTRACT Backgrounds and Aims Type 2 diabetes and its complications are assumed to be major public health problems globally. Zinc is one of the elements that play a part in insulin secretion and signaling. Therefore, this study seeks the answer to the following question: “What are the effects of 220...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.70375 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583149504167936 |
|---|---|
| author | Mehrab Sayadi Sara Javadpour Nowbandegani Fatemeh Balaghi Inalou Bahman Nazemzadegan Shirzad Javidi Alsaadi Mohammadreza Eskandari Matin Sepehrinia |
| author_facet | Mehrab Sayadi Sara Javadpour Nowbandegani Fatemeh Balaghi Inalou Bahman Nazemzadegan Shirzad Javidi Alsaadi Mohammadreza Eskandari Matin Sepehrinia |
| author_sort | Mehrab Sayadi |
| collection | DOAJ |
| description | ABSTRACT Backgrounds and Aims Type 2 diabetes and its complications are assumed to be major public health problems globally. Zinc is one of the elements that play a part in insulin secretion and signaling. Therefore, this study seeks the answer to the following question: “What are the effects of 220 mg zinc sulfate supplementation on the weight, blood pressure, and glycemic control of patients with Type 2 diabetes?”. Methods In this randomized controlled double‐blind trial, 79 patients with Type 2 diabetes were allocated into two groups through permuted block randomization method. The study group received two capsules of 220 mg of zinc sulfate containing 50 mg of zinc, and the control group received two capsules of 220 mg of placebo ingredient per week for 12 weeks. At the start and end of the treatment period, the fasting blood glucose (FBG), glycated hemoglobin (HbA1c), zinc level, weight, waist circumference (WC), and blood pressure were measured. Results After 12 weeks of follow‐up, 72 patients completed the study. There were no significant differences before and after the intervention in the FBG, HbA1c, zinc levels, and WC between the two groups. Intragroup analysis showed that weight and body mass index increased in the intervention group; however, these changes were not significant in comparison to the control group. Also, diastolic blood pressure significantly increased in the control group; however, changes in systolic blood pressure were not significant in both groups. Conclusion Taking 220 mg of zinc sulfate supplement twice a week did not show significant benefit for weight, blood pressure, and glycemic control in patients with Type 2 diabetes. Trial Registration This trial was registered on the Iranian Registry of Clinical Trials (IRCT) website with code number 29627 on September 18, 2018. |
| format | Article |
| id | doaj-art-392b67a8ba1e43d9b364afc59fd9cb99 |
| institution | Kabale University |
| issn | 2398-8835 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj-art-392b67a8ba1e43d9b364afc59fd9cb992025-01-29T03:42:39ZengWileyHealth Science Reports2398-88352025-01-0181n/an/a10.1002/hsr2.70375The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double‐Blind Randomized Controlled TrialMehrab Sayadi0Sara Javadpour Nowbandegani1Fatemeh Balaghi Inalou2Bahman Nazemzadegan3Shirzad Javidi Alsaadi4Mohammadreza Eskandari5Matin Sepehrinia6Cardiovascular Research Center Shiraz University of Medical Sciences Shiraz IranNon‐Communicable Diseases Unit, Vice Chancellor of Health Shiraz University of Medical Sciences Shiraz IranNon‐Communicable Diseases Unit, Vice Chancellor of Food and Drug Administration Shiraz University of Medical Sciences Shiraz IranNon‐Communicable Diseases Unit, Vice Chancellor of Health Shiraz University of Medical Sciences Shiraz IranNon‐Communicable Diseases Unit, Vice Chancellor of Health Shiraz University of Medical Sciences Shiraz IranDepartment of Pharmacology and Toxicology, School of Pharmacy Zanjan University of Medical Sciences Zanjan IranNoncommunicable Diseases Research Center Fasa University of Medical Sciences Fasa IranABSTRACT Backgrounds and Aims Type 2 diabetes and its complications are assumed to be major public health problems globally. Zinc is one of the elements that play a part in insulin secretion and signaling. Therefore, this study seeks the answer to the following question: “What are the effects of 220 mg zinc sulfate supplementation on the weight, blood pressure, and glycemic control of patients with Type 2 diabetes?”. Methods In this randomized controlled double‐blind trial, 79 patients with Type 2 diabetes were allocated into two groups through permuted block randomization method. The study group received two capsules of 220 mg of zinc sulfate containing 50 mg of zinc, and the control group received two capsules of 220 mg of placebo ingredient per week for 12 weeks. At the start and end of the treatment period, the fasting blood glucose (FBG), glycated hemoglobin (HbA1c), zinc level, weight, waist circumference (WC), and blood pressure were measured. Results After 12 weeks of follow‐up, 72 patients completed the study. There were no significant differences before and after the intervention in the FBG, HbA1c, zinc levels, and WC between the two groups. Intragroup analysis showed that weight and body mass index increased in the intervention group; however, these changes were not significant in comparison to the control group. Also, diastolic blood pressure significantly increased in the control group; however, changes in systolic blood pressure were not significant in both groups. Conclusion Taking 220 mg of zinc sulfate supplement twice a week did not show significant benefit for weight, blood pressure, and glycemic control in patients with Type 2 diabetes. Trial Registration This trial was registered on the Iranian Registry of Clinical Trials (IRCT) website with code number 29627 on September 18, 2018.https://doi.org/10.1002/hsr2.70375diabetes mellitustrace elementszinc |
| spellingShingle | Mehrab Sayadi Sara Javadpour Nowbandegani Fatemeh Balaghi Inalou Bahman Nazemzadegan Shirzad Javidi Alsaadi Mohammadreza Eskandari Matin Sepehrinia The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double‐Blind Randomized Controlled Trial Health Science Reports diabetes mellitus trace elements zinc |
| title | The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double‐Blind Randomized Controlled Trial |
| title_full | The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double‐Blind Randomized Controlled Trial |
| title_fullStr | The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double‐Blind Randomized Controlled Trial |
| title_full_unstemmed | The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double‐Blind Randomized Controlled Trial |
| title_short | The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double‐Blind Randomized Controlled Trial |
| title_sort | effect of zinc supplementation on glycemic weight and blood pressure control in patients with type 2 diabetes mellitus a double blind randomized controlled trial |
| topic | diabetes mellitus trace elements zinc |
| url | https://doi.org/10.1002/hsr2.70375 |
| work_keys_str_mv | AT mehrabsayadi theeffectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT sarajavadpournowbandegani theeffectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT fatemehbalaghiinalou theeffectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT bahmannazemzadegan theeffectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT shirzadjavidialsaadi theeffectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT mohammadrezaeskandari theeffectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT matinsepehrinia theeffectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT mehrabsayadi effectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT sarajavadpournowbandegani effectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT fatemehbalaghiinalou effectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT bahmannazemzadegan effectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT shirzadjavidialsaadi effectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT mohammadrezaeskandari effectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial AT matinsepehrinia effectofzincsupplementationonglycemicweightandbloodpressurecontrolinpatientswithtype2diabetesmellitusadoubleblindrandomizedcontrolledtrial |